Cargando…

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

Bladder cancer therapy relies on aggressive treatments highlighting the need for new, targeted therapies with reduced side effects. SWI/SNF complexes are mutated in ~20% across human cancers and dependency of SWI/SNF-deficient tumors on EZH2 has been uncovered recently. To systematically dissect the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garczyk, Stefan, Schneider, Ursula, Lurje, Isabella, Becker, Katharina, Vögeli, Thomas A., Gaisa, Nadine T., Knüchel, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107234/ https://www.ncbi.nlm.nih.gov/pubmed/30138427 http://dx.doi.org/10.1371/journal.pone.0202965

Ejemplares similares

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
por: Barth, Isabella, et al.
Publicado: (2018)

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy
por: Schnitzler, Tician, et al.
Publicado: (2020)

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2022)

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2021)

SWI/SNF Alterations in Squamous Bladder Cancers
por: Achenbach, Fabian, et al.
Publicado: (2020)

Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma
por: Lurje, Isabella, et al.
Publicado: (2023)

Epigenetic inactivation of ST6GAL1 in human bladder cancer
por: Antony, Pia, et al.
Publicado: (2014)

Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
por: Wucherpfennig, Sophie, et al.
Publicado: (2021)

Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection
por: Miller, Hannah, et al.
Publicado: (2020)

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
por: Morsch, Ronja, et al.
Publicado: (2020)

Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR
por: Chughtai, Ahmed Ali, et al.
Publicado: (2022)

Molecular Characterization of Muellerian Tumors of the Urinary Tract
por: Ortiz-Brüchle, Nadina, et al.
Publicado: (2021)

The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells
por: Rose, Michael, et al.
Publicado: (2021)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma
por: Cao, Qifeng, et al.
Publicado: (2019)

Comparative genomic profiling of glandular bladder tumours
por: Maurer, Angela, et al.
Publicado: (2020)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population
por: Zhou, Xiaozhou, et al.
Publicado: (2018)

ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer
por: Rose, Michael, et al.
Publicado: (2020)

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer
por: Humayun-Zakaria, Nada, et al.
Publicado: (2019)

Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer
por: Mijnes, Jolein, et al.
Publicado: (2018)

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2013)

Correction: ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2014)

Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma
por: Wang, Beihe, et al.
Publicado: (2017)

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2
por: Li, Bo, et al.
Publicado: (2019)

AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection
por: Garczyk, Stefan, et al.
Publicado: (2015)

Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway
por: Garczyk, Stefan, et al.
Publicado: (2017)

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
por: Rose, Michael, et al.
Publicado: (2020)

Intraoperative Transfusion of Fresh Frozen Plasma Predicts Morbidity Following Partial Liver Resection for Hepatocellular Carcinoma
por: Bednarsch, Jan, et al.
Publicado: (2020)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features
por: Yu, Yung-Luen, et al.
Publicado: (2014)

Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
por: Piunti, Andrea, et al.
Publicado: (2022)

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)

Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal
por: Biter, Benjamin G., et al.
Publicado: (2015)

Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7
por: Bolenz, Christian, et al.
Publicado: (2018)

Prioritizing potential circRNA biomarkers for bladder cancer and bladder urothelial cancer based on an ensemble model
por: Su, Qiongli, et al.
Publicado: (2022)

Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
por: McNeil, Brian K, et al.
Publicado: (2014)

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma
por: Liu, Mulin, et al.
Publicado: (2021)

Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
por: Humayun-Zakaria, Nada, et al.
Publicado: (2021)

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
por: Alldredge, Jill K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0sp3v2el8da8iu222mjagn13pa